Accelerated testing and development to benefit patients as soon as possible.
We have a first-in-category platform that enables acceleration of drug research and development.
KAN-001, targeting Cancer Immunotherapy Potentiation, Lead Selection 50% completed In partnership with MD Anderson Cancer Center
Cancer immunotherapy has revolutionized cancer treatment, yet a significant proportion of patients do not respond. Our data, along with many other studies, suggest the constituents of the gut microbiome are critically important for the equilibrium of the immune system, which allows a positive immunotherapy response. We are developing KAN-001 as a synergistic therapy to prime the immune system and increase the overall response rate and survival in immunotherapy-eligible cancer patients.
KAN-002, targeting Inflammatory Bowel Disease, Phase 1 75% completed Exploring Strategic Partnerships
IBD is a multifactorial disease that results in a chronic inflammatory condition of the gastrointestinal tract. Dysbiosis of the gut microbiome has long been implicated in the start and progression of this debilitating disease. We have developed a metabolically complete microbiome replacement therapy in KAN-002, with the potential to restore intestinal barrier function, decrease inflammation, and improve quality of life.
Harnessing the 9th organ system.
Our technology platforms can address all regulatory requirements and accelerate critical steps along the drug development pathway.
This will enable us to establish the microbiome as the vital 9th organ system, driving new insights, increasing legitimate therapeutic options, and ultimately improving personalized patient care.